Dr Volker Schellenberger | Chief Executive Officer & President
Amunix Inc

Dr Volker Schellenberger, Chief Executive Officer & President, Amunix Inc

Volker Schellenberger is President and CEO of Amunix Operating Inc, which he co-founded with Willem Pim Stemmer in 2006. He initially served as Amunix’ Chief Scientific Officer and is the lead inventor of the company’s XTEN  as well as ProTIA platforms. Volker has over 20 years of industry experience in protein engineering and drug discovery. Prior to co-founding Amunix he served as head of Genencor’s protein engineering department.
Volker received his Ph.D. from Leipzig University (Germany) in 1986. After postdoctoral work at the Institute for Protein Research in Pushchino (Russia), the University of Göttingen. and with Bill Rutter at the University of California, San Francisco he joined Genencor in 1994. Volker is author of over 40 scientific papers and inventor of more than 70 issued or pending patent applications. He is a recipient of the Karl Lohmann prize of the German Society of Biochemists.


EAC 2017 Day 2, Wednesday 1st November 2017 @ 12:45

ProTIA – Bispecific T cell engagers designed for local activation by tumor-associated proteas

  • ProTIA molecules utilize our proprietary XTEN™ protein polymer for half-life extension and to enable rapid microbial production as single protein chain
  • The XTENylated form of ProTIAs forms an inactive precursors with low systemic toxicity
  • XTEN is released at the tumor site by tumor associated proteases resulting in a 300-1000x gain in activity
  • ProTIA combines multiple mechanisms that contribute to the therapeutic index: A) Tumor antigen binding; B) Selective activation at the tumor site, C) The preferential accumulation of polymers in the tumor environment (EPR effect)

back to speakers